Legend Biotech Corporation (LEGN) has released an update.
Legend Biotech Corporation announced preliminary net trade sales of approximately $157 million for its drug CARVYKTI® for the quarter ending March 31, 2024. These figures are based on reports from Janssen Biotech, Inc. under a collaboration and license agreement, and have yet to be independently verified or audited by Legend Biotech. The company cautions that these forward-looking statements are subject to various significant risks and uncertainties that may cause actual results to differ materially.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
